Fondaparinux: An overview

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 6, 2009, Pages 577-585

  Nadar, Sunil K ^a   Goyal, Deepak ^a   Shantsila, Eduard ^b   Banerjee, Pritwish ^a   Lip, Gregory Y H ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Anticoagulant; Factor Xa; Fondaparinux

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; POLYSACCHARIDE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; CATHETER THROMBOSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART TAMPONADE; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; THROMBOPLASTIN TIME; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG INTERACTION; METHODOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DRUG INTERACTIONS; ENOXAPARIN; FACTOR XA; HUMANS; POLYSACCHARIDES; VENOUS THROMBOEMBOLISM;

EID: 68849093755     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.19     Document Type: Review

References (32)

1. Petitou M, Duchaussoy P, Driguez PA, Herault JP, Lormeau JC, Herbert JM. New synthetic heparin mimetics able to inhibit thrombin and Factor Xa. Bioorg. Med. Chem. Lett. 9(8), 1155-1160 (1999).
2. Petitou M, Hérault JP, Bernat A et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398(6726), 417-422 (1999).
3. Paolucci F, Clavies MC, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin. Pharmacokinet. 41(Suppl. 2), 11-18 (2002).
4. Beguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost. 61(3), 397-401 (1989).
5. Smogorzewska A, Brandt JT, Chandler WL et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch. Pathol. Lab. Med. 130(11), 1605-1611 (2006).
6. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. 41(Suppl. 2), 1-9 (2002).
7. Lieu C, Shi J, Donat F et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin. Pharmacokinet. 41(Suppl. 2), 19-26 (2002).
8. Mant T, Fournie P, Ollier C, Donat F, Necciari J. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin. Pharmacokinet. 41(Suppl. 2), 39-45 (2002).
9. Ollier C, Faaij RA, Santoni A et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin. Pharmacokinet. 41(Suppl. 2), 31-37 (2002).
10. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J. South Orthop. Assoc. 11(4), 182-188 (2002).
11. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 163(11), 1337-1342 (2003).
12. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative daltepatin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg. 92(10), 1212-1220 (2005).
13. Eikelboom JW. Effect of fondaparinux 2.5 mg once daily on mortality: a meta analysis of Phase III randomized trials of venous thromboembolism prevention. Eur. Heart J. 10(Suppl. C), C8-C13 (2008).
14. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-Factor Xa activity: a Phase II evaluation. Circulation 102(22), 2726-2731 (2000).
15. Büller HR, Davidson BL, Decousus H et al.; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. 140(11), 867-873 (2004).
16. Büller HR, Davidson BL, Decousus H et al.; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349(18), 1695-1702 (2003).
17. O'Donoghue M, Boden WE, Braunwald E et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 300(1), 71-80 (2008).
18. Simoons ML, Bobbink IW, Boland J et al.; PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J. Am. Coll. Cardiol. 43(12), 2183-2190 (2004).
19. Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. 50(18), 1742-1751 (2007).
20. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302), 189-198 (2002).
21. Yusuf S, Zhao F, Mehta SR, Chrolavicius S. Effects of dopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
22. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114, 774-782 (2006).
23. Coussement PK, Bassand JP, Convens C et al.; PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 22(18), 1716-1724 (2001).
24. Yusuf S, Mehta SR, Chrolavicius S et al.; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized tial. JAMA 295(13), 1519-1530 (2006).
25. Peters RJ, Joyner C, Bassand JP, Afzal R, Cholavicius S, Mehta SR. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur. Heart J. 29(3), 324-331 (2008).
26. Oldgren J, Wallentin L, Afzal R et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur. Heart J. 29(3), 315-323 (2008).
27. Bassand JP, Hamm CW, Ardissino D et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. The task force for the diagnosis and treatment of Non ST segment elevation acute coronary symdromes of European society of cardiology. Guidelines for the diagnosis and treatment of non ST segment elevation acute coronary syndromes. Eur. Heart J. 28, 1598-1660 (2007).
28. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the Americal College of Cardiology/ American heart association task force on practical guidelines. J. Am. Coll. Cardiol. 50, e1-e157 (2007).
29. Schlitt A, Hamilton K, Maegdefessel L. et al. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. J. Heart Valve Dis. 15(6), 809-814 (2006).
30. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 108(5), 1569-1570 (2006).
31. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin. Thromb. Hemost. 32(8), 803-809 (2006).
32. Viles-Gonzalez JF, Gaztanaga J, Zafar UM, Fuster V, Badimon JJ. Clinical and experimental experience with Factor Xa inhibitors. Am. J. Cardiovasc. Drugs 4(6), 379-384 (2004).